1Baine WB,Yu W,Summe JP,et al. Epidemiologic trends in the evaluation and treatment of lower urinary tract symptoms in elderly male medicare patients from 1991 to 1995. J Urol, 1998,160:816-820.
2Lepor H. α-aderenergic blocker for the treatment of benign prostatic hyperplasia.In:Lepor H eds. Prostatic diseases. Philadelphia: Saunders ,2001. 297-307.
3McConnell JD. Androgen suppression in the management of benign prostatic hyperplasia. In: Lepor H eds. Prostatic diseases. Philadelphia: Saunders, 2001. 308 -320.
4Debruyne FM,Jardin A,Colloi D,et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol, 1998,34:169 -175.
5Lepor H,Williford WO,Barry MJ,et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med,1996,335:533-539.
6Kirby RS,Roehrborn C,Boyle P,et al. Efficacy and tolerability of doxazosin and finasteride,alone or in combination,in treatment of symptomatic benign prostatic hyperplasia:the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology ,2003,61:119-126.
7McConnell JD, Roehrborn CG, Bautista OM,et al. The long-term effect of doxazosin,finasteride,and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med, 2003,349: 2387-2398.
8Baldwin KC,Ginsberg PC,Roehrborn CG,et al. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology, 2001, 58:203 -209.
9Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective,randomized,controlled study. J Urol,2003,169:2253-2256.
10Di Silverio F,Bosman G,Salvatori M,et al.Gombination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol,2005,47:72-79.
